Ingredients

Pfizer, Bayer, and BMS Advance Personalized-Medicine Products

February 11, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

Personalized medicine is still a nascent area for pharmaceutical companies, but several large companies recently reported developments in this area.

GSK Plans Further Restructuring in R&D

February 11, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

GSK Chief Executive Andrew Witty outlined the company's strategic priorities for 2010, which include further diversification into emerging markets, consumer healthcare, and vaccines.

FDA Unveils PREDICT System for Import Inspections

February 11, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

Margaret Hamburg, commissioner of the US Food and Drug Administration, unveiled a new program to improve the efficiency of import inspections.

Week Of Feb. 8, 2010: Company And People Notes: VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

February 11, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

Pfizer Streamlines and Prioritizes Pipeline

February 04, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer's first updated pipeline since its acquisition of Wyeth includes fewer projects than before and is targeted to specific diseases.

Week of Feb. 1, 2010: Company and People Notes: Cephalon Buys Mepha; BASi's CEO Retires; and More.

February 04, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

Cephalon Buys Mepha; BASi's CEO Retires; and More.

AstraZeneca Announces Jobs Cuts and R&D Restructuring

February 04, 2010

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca announced this week that it plans to undertake further restructuring in its research and development operations, resulting in the elimination of 3500 jobs.